129 related articles for article (PubMed ID: 35316569)
1. Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001.
Athale UH; Flamand Y; Blonquist T; Stevenson KE; Spira M; Asselin BL; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Harris MH; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2022 Aug; 69(8):e29581. PubMed ID: 35316569
[TBL] [Abstract][Full Text] [Related]
2. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.
Athale UH; Laverdiere C; Nayiager T; Delva YL; Foster G; Thabane L; Chan AK
BMC Cancer; 2017 May; 17(1):313. PubMed ID: 28472942
[TBL] [Abstract][Full Text] [Related]
3. Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluation.
Athale UH; Mizrahi T; Laverdière C; Nayiager T; Delva YL; Foster G; Thabane L; David M; Leclerc JM; Chan AKC
Pediatr Blood Cancer; 2018 May; 65(5):e26938. PubMed ID: 29334169
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.
Tuckuviene R; Ranta S; Albertsen BK; Andersson NG; Bendtsen MD; Frisk T; Gunnes MW; Helgestad J; Heyman MM; Jonsson OG; Mäkipernaa A; Pruunsild K; Tedgård U; Trakymiene SS; Ruud E
J Thromb Haemost; 2016 Mar; 14(3):485-94. PubMed ID: 26707629
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and safety of delivering full-dose anticoagulation therapy in children treated according to Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium therapy protocols.
Bhatt MD; Parmar N; Fowler JA; Chan AKC; Athale UH
Pediatr Blood Cancer; 2019 Feb; 66(2):e27483. PubMed ID: 30362248
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
Athale UH; Siciliano SA; Crowther M; Barr RD; Chan AK
Br J Haematol; 2005 Jun; 129(6):803-10. PubMed ID: 15953008
[TBL] [Abstract][Full Text] [Related]
7.
Mootoosamy C; Kondyli M; Serfaty SA; Tremblay DÉ; Gagné V; Ribère M; Laverdière C; Leclerc JM; Sinnett D; Tran TH; Krajinovic M
Pharmacogenomics; 2023 Mar; 24(4):199-206. PubMed ID: 36946317
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors.
Nowak-Göttl U; Wermes C; Junker R; Koch HG; Schobess R; Fleischhack G; Schwabe D; Ehrenforth S
Blood; 1999 Mar; 93(5):1595-9. PubMed ID: 10029588
[TBL] [Abstract][Full Text] [Related]
9. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia.
Athale UH; Chan AK
Thromb Res; 2003; 111(3):125-31. PubMed ID: 14678808
[TBL] [Abstract][Full Text] [Related]
10. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.
Grace RF; Dahlberg SE; Neuberg D; Sallan SE; Connors JM; Neufeld EJ; Deangelo DJ; Silverman LB
Br J Haematol; 2011 Feb; 152(4):452-9. PubMed ID: 21210774
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
Nowak-Göttl U; Heinecke A; von Kries R; Nürnberger W; Münchow N; Junker R
Thromb Res; 2001 Aug; 103(3):165-72. PubMed ID: 11672578
[TBL] [Abstract][Full Text] [Related]
12. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
[TBL] [Abstract][Full Text] [Related]
13. Thrombosis in children with acute lymphoblastic leukemia Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment.
Athale UH; Chan AK
Thromb Res; 2003; 111(6):321-7. PubMed ID: 14698648
[TBL] [Abstract][Full Text] [Related]
14. Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: A report from CYP-C.
Pelland-Marcotte MC; Kulkarni K; Athale UH; Pole JD; Brandão LR; Sung L
Am J Hematol; 2021 Jul; 96(7):796-804. PubMed ID: 33848369
[TBL] [Abstract][Full Text] [Related]
15. Polygenic risk score-analysis of thromboembolism in patients with acute lymphoblastic leukemia.
Jarvis KB; Nielsen RL; Gupta R; Hede FD; Huttunen P; Jónsson ÓG; Rank CU; Ranta S; Saks K; Trakymiene SS; Tuckuviene R; Tulstrup M; ; Ruud E; Schmiegelow K; LeBlanc M
Thromb Res; 2020 Dec; 196():15-20. PubMed ID: 32818716
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: A report from CYP-C.
Pelland-Marcotte MC; Kulkarni K; Tran TH; Stammers D; Gupta S; Sung L; Athale UH
Am J Hematol; 2024 Feb; 99(2):274-283. PubMed ID: 38164978
[TBL] [Abstract][Full Text] [Related]
17. Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia - A NOPHO ALL2008 study.
Jarvis KB; LeBlanc M; Tulstrup M; Nielsen RL; Albertsen BK; Gupta R; Huttunen P; Jónsson ÓG; Rank CU; Ranta S; Ruud E; Saks K; Trakymiene SS; Tuckuviene R; Schmiegelow K
Thromb Res; 2019 Dec; 184():92-98. PubMed ID: 31715544
[TBL] [Abstract][Full Text] [Related]
18. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
19. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
[TBL] [Abstract][Full Text] [Related]
20. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
